USANA Health Sciences Reports Mixed Q1 Results, Reaffirms 2026 Outlook Amidst Omnichannel Transformation

summarizeSummary

USANA Health Sciences reported flat Q1 net sales of $250 million but a 20% year-over-year decline in net earnings to $7.5 million, while reaffirming its full-year 2026 guidance.

check_boxKey Events

• Q1 2026 Financial Performance

  Net sales were flat year-over-year at $250 million, but net earnings decreased 20% to $7.5 million, and diluted EPS fell 16% to $0.41. Adjusted diluted EPS also declined 16% to $0.61.

• Full-Year 2026 Guidance Reaffirmed

  The company reiterated its fiscal year 2026 outlook for consolidated net sales ($925M-$1.0B), net earnings ($20M-$27M), and diluted EPS ($1.11-$1.45), signaling confidence in its strategic plan.

• Sequential Improvements Noted

  Despite year-over-year declines in profitability, the company reported sequential improvements with net sales up 11%, adjusted diluted EPS up 2%, and Core Nutritional active customers up 4% from Q4 2025.

• Omnichannel Transformation Progress

  The Rise Wellness segment saw significant growth, with net sales increasing 741% year-over-year to $14 million, driven by the launch of Protein Pop Plus into Costco. Hiya Health net sales decreased 13% year-over-year but showed sequential improvement.

auto_awesomeAnalysis

USANA Health Sciences reported a mixed first quarter, with net sales remaining flat year-over-year at $250 million, which aligns with analyst estimates previously reported by Reuters. However, net earnings saw a significant 20% decline to $7.5 million, continuing a trend of profitability challenges noted in the prior year's 10-K. Despite these year-over-year pressures, the company demonstrated meaningful sequential improvements in net sales, adjusted diluted EPS, and active customer counts, suggesting early positive impacts from its strategic omnichannel transformation. The reiteration of the full-year 2026 guidance across all metrics is a key takeaway, indicating management's confidence in achieving its targets despite the Q1 profit drop. Investors will be watching for continued sequential improvements and the successful execution of the omnichannel strategy, particularly the growth and margin progression of the Hiya and Rise Wellness segments.